Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study
- Location
-
Deutsche Nationalbibliothek Frankfurt am Main
- Extent
-
1 Online-Ressource.
- Language
-
Englisch
- Bibliographic citation
-
Dexamethasone is non-inferior to antihistamine plus dexamethasone premedication in preventing ramucirumab plus nab-paclitaxel infusion-related reactions in gastric cancer: a multicenter retrospective study ; volume:32 ; number:10 ; day:7 ; month:10 ; year:2024 ; pages:1-7 ; date:10.2024
Supportive care in cancer ; 32, Heft 10 (7.10.2024), 1-7, 10.2024
- Creator
-
Negoro, Yutaka
Maeda, Taichi
Igarashi, Hiroyuki
Shigemori, Mina
Tanaka, Toshihiro
Ito, Yukio
Tanizawa, Norihiko
Nishikawa, Shota
Ogawa, Jyunya
Kamitani, Yukio
Watanabe, Kyohei
Tsukamoto, Hitoshi
Goto, Nobuyuki
- Contributor
-
SpringerLink (Online service)
- DOI
-
10.1007/s00520-024-08910-8
- URN
-
urn:nbn:de:101:1-2501082102295.568627858790
- Rights
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Last update
-
15.08.2025, 7:36 AM CEST
Data provider
This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.
Associated
- Negoro, Yutaka
- Maeda, Taichi
- Igarashi, Hiroyuki
- Shigemori, Mina
- Tanaka, Toshihiro
- Ito, Yukio
- Tanizawa, Norihiko
- Nishikawa, Shota
- Ogawa, Jyunya
- Kamitani, Yukio
- Watanabe, Kyohei
- Tsukamoto, Hitoshi
- Goto, Nobuyuki
- SpringerLink (Online service)
Other Objects (12)
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma
Mcl-1 expression is a predictive marker of response to gemcitabine plus nab-paclitaxel for metastatic pancreatic cancer
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
Nab-paclitaxel and gemcitabine plus camrelizumab and radiotherapy versus nab-paclitaxel and gemcitabine alone for locally advanced pancreatic adenocarcinoma: a prospective cohort study
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Necrosis of Pedunculated Lipofibroma by Nab-Paclitaxel
Nab-paclitaxel plus platinum versus paclitaxel plus platinum as first-line therapy in patients with metastatic or recurrent cervical cancer
Leptomeningeal Carcinomatosis in a Patient with Pancreatic Cancer Responding to Nab-Paclitaxel plus Gemcitabine
Neoadjuvant nab-paclitaxel in the treatment of breast cancer
Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer
Nab-Paclitaxel + Carboplatin bei fortgeschrittenem NSCLC : Fallsamlung von 7 Kasuistiken
Phase I/II dose-finding study of nanoparticle albumin-bound paclitaxel (nab®-Paclitaxel) plus Cisplatin as Treatment for Metastatic Nasopharyngeal Carcinoma